Healthcare stakeholders throughout U.S. medicine, including radiology leaders, aren’t waiting for the ink to dry before speaking their minds.

Women with dense breasts or other heightened risk factors for breast cancer may be on the cusp of receiving 100% coverage for additional imaging beyond standard mammography.

The Dallas-based company says its product incorporates bias-busting algorithms that overcome the lack of diverse populations available for model training.

A molecular contrast agent previously cleared for use during surgery for ovarian cancer may now be used in similar fashion during lung operations.

The gain came with the delayed discovery of only a few clinically significant cancers.